BIOMAT Database Logo BIOMAT Database Logo

[Cutaneous vasculitis during pergolide mesylate treatment]. 2002

J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor

UI MeSH Term Description Entries
D010479 Pergolide A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES. Celance,LY-127,809,LY-127809,Parkotil,Pergolide Mesylate,Permax,Pharken,LY127,809,LY127809,Mesylate, Pergolide
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D018366 Vasculitis, Leukocytoclastic, Cutaneous Disorder characterized by a vasculitic syndrome associated with exposure to an antigen such as a drug, infectious agent, or other foreign or endogenous substance. Its pathophysiology includes immune complex deposition and a wide range of skin lesions. Hypersensitivity or allergy is present in some but not all cases. Angiitis, Hypersensitivity,Cutaneous Leukocytoclastic Vasculitis,Hypersensitivity Angiitis,Hypersensitivity Vasculitis,Vasculitis, Hypersensitivity,Allergic Cutaneous Angiitis,Allergic Cutaneous Vasculitis,Angiitis, Allergic Cutaneous,Cutaneous Allergic Vasculitis,Cutaneous Leukocytoclastic Angiitis,Vasculitis, Allergic Cutaneous,Allergic Cutaneous Angiitides,Allergic Cutaneous Vasculitides,Allergic Vasculitides, Cutaneous,Allergic Vasculitis, Cutaneous,Angiitides, Allergic Cutaneous,Angiitides, Cutaneous Leukocytoclastic,Angiitides, Hypersensitivity,Angiitis, Cutaneous Leukocytoclastic,Cutaneous Allergic Vasculitides,Cutaneous Angiitides, Allergic,Cutaneous Angiitis, Allergic,Cutaneous Leukocytoclastic Angiitides,Cutaneous Leukocytoclastic Vasculitides,Cutaneous Vasculitides, Allergic,Cutaneous Vasculitis, Allergic,Hypersensitivity Angiitides,Hypersensitivity Vasculitides,Leukocytoclastic Angiitides, Cutaneous,Leukocytoclastic Angiitis, Cutaneous,Leukocytoclastic Vasculitides, Cutaneous,Leukocytoclastic Vasculitis, Cutaneous,Vasculitides, Allergic Cutaneous,Vasculitides, Cutaneous Allergic,Vasculitides, Cutaneous Leukocytoclastic,Vasculitides, Hypersensitivity,Vasculitis, Cutaneous Allergic,Vasculitis, Cutaneous Leukocytoclastic
D018491 Dopamine Agonists Drugs that bind to and activate dopamine receptors. Dopamine Receptor Agonists,Dopaminergic Agonists,Agonists, Dopamine Receptor,Agonists, Dopaminergic,Dopamine Agonist,Dopamine Receptor Agonist,Dopaminergic Agonist,Receptor Agonists, Dopamine,Agonist, Dopamine,Agonist, Dopamine Receptor,Agonist, Dopaminergic,Agonists, Dopamine,Receptor Agonist, Dopamine

Related Publications

J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
Pergolide mesylate treatment of cocaine withdrawal.
January 1991, The Journal of clinical psychiatry,
J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
Pergolide mesylate in Parkinson's disease treatment.
January 1995, Journal of neural transmission. Supplementum,
J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
[Treatment of hyperprolactinemias by pergolide mesylate].
January 1987, Presse medicale (Paris, France : 1983),
J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
Pergolide mesylate form II.
October 2003, Acta crystallographica. Section C, Crystal structure communications,
J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
Cutaneous Vasculitis During Secukinumab Treatment.
January 2020, European journal of case reports in internal medicine,
J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
Psychoactive properties of pergolide mesylate.
January 1995, Journal of psychoactive drugs,
J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
[Sleep attacks and pergolide mesylate].
February 2001, Neurologia (Barcelona, Spain),
J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
Cutaneous leucocytoclastic vasculitis during secukinumab treatment.
December 2021, Italian journal of dermatology and venereology,
J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
Pergolide mesylate and idiopathic Parkinson disease.
October 1982, Neurology,
J Serratrice, and B Granel, and P Disdier, and P J Weiller, and P Alcaraz, and J P Azulay, and M J Jean-Pastor
Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
April 1983, British medical journal (Clinical research ed.),
Copied contents to your clipboard!